JPWO2021112106A1 - - Google Patents

Info

Publication number
JPWO2021112106A1
JPWO2021112106A1 JP2021562674A JP2021562674A JPWO2021112106A1 JP WO2021112106 A1 JPWO2021112106 A1 JP WO2021112106A1 JP 2021562674 A JP2021562674 A JP 2021562674A JP 2021562674 A JP2021562674 A JP 2021562674A JP WO2021112106 A1 JPWO2021112106 A1 JP WO2021112106A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021562674A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021112106A1 publication Critical patent/JPWO2021112106A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021562674A 2019-12-02 2020-12-02 Pending JPWO2021112106A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019218038 2019-12-02
PCT/JP2020/044768 WO2021112106A1 (ja) 2019-12-02 2020-12-02 色素性乾皮症ｆ群治療薬

Publications (1)

Publication Number Publication Date
JPWO2021112106A1 true JPWO2021112106A1 (zh) 2021-06-10

Family

ID=76221697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562674A Pending JPWO2021112106A1 (zh) 2019-12-02 2020-12-02

Country Status (3)

Country Link
JP (1) JPWO2021112106A1 (zh)
TW (1) TW202134438A (zh)
WO (1) WO2021112106A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026887A1 (en) * 1993-05-11 1994-11-24 The University Of North Carolina At Chapel Hill Antisense oligonucleotides which combat aberrant splicing and methods of using the same
GB201410693D0 (en) * 2014-06-16 2014-07-30 Univ Southampton Splicing modulation

Also Published As

Publication number Publication date
TW202134438A (zh) 2021-09-16
WO2021112106A1 (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
BR112021017339A2 (zh)
BR112021018450A2 (zh)
BR112021017892A2 (zh)
BR112021017939A2 (zh)
BR112021017782A2 (zh)
BR112021018168A2 (zh)
BR112021017728A2 (zh)
BR112021017234A2 (zh)
BR112021017355A2 (zh)
BR112021017173A2 (zh)
BR112021018102A2 (zh)
BR112021017083A2 (zh)
BR112021017637A2 (zh)
BR112021008711A2 (zh)
BR112021018452A2 (zh)
BR112021018250A2 (zh)
BR112021018093A2 (zh)
BR112021018084A2 (zh)
BR112021017703A2 (zh)
BR112021013128A2 (zh)
BR112021018484A2 (zh)
BR112021017732A2 (zh)
BR112021017949A2 (zh)
BR112021017983A2 (zh)
BR112021016996A2 (zh)

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220601

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231018